| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
A first-generation EGFR TKI used for NSCLC by competing with ATP for EGFR kinase binding. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Another first-generation EGFR TKI inhibiting EGFR kinase activity, approved for NSCLC and pancreatic cancer. | ||||||
Afatinib-d4 | 850140-72-6 (unlabeled) | sc-481821 | 10 mg | $4665.00 | ||
A second-generation EGFR TKI that irreversibly binds EGFR kinase domain, approved for NSCLC. | ||||||
Osimertinib | 1421373-65-0 | sc-507355 | 5 mg | $86.00 | ||
A third-generation EGFR TKI targeting mutated EGFR, effective against NSCLC. | ||||||